Subscribe To
Jefferies cuts netflix price target by 44%
Jefferies analyst Andrew Uerkwitz downgraded Netflix Inc (NASDAQ:NFLX) to Hold from Buy with a price target of $415, down from $737, suggesting a...
January 24, 2022, 10:11 am
Jefferies cuts netflix price target by 44%
Jefferies analyst Andrew Uerkwitz downgraded Netflix Inc (NASDAQ:NFLX) to Hold from Buy with a price target of $415, down from $737, suggesting a...
January 24, 2022, 10:11 am
Big tech's three biggest regulatory threats
When the Senate Judiciary Committee voted last Thursday to advance the American Innovation and Choice Online Act, a bipartisan antitrust bill, it set ...
January 24, 2022, 10:00 am
Big tech's three biggest regulatory threats
When the Senate Judiciary Committee voted last Thursday to advance the American Innovation and Choice Online Act, a bipartisan antitrust bill, it set ...
January 24, 2022, 10:00 am
Big tech's three biggest regulatory threats
When the Senate Judiciary Committee voted last Thursday to advance the American Innovation and Choice Online Act, a bipartisan antitrust bill, it set ...
January 24, 2022, 10:00 am
Tesla has the ability to follow amazon's path, says canaccord genuity analyst
Gordon Johnson, founder and CEO of GLJ Research, and Jed Dorsheimer, analyst at Canaccord Genuity, join CNBC's 'Squawk Box' to break down what investo...
January 24, 2022, 9:36 am
Tesla has the ability to follow amazon's path, says canaccord genuity analyst
Gordon Johnson, founder and CEO of GLJ Research, and Jed Dorsheimer, analyst at Canaccord Genuity, join CNBC's 'Squawk Box' to break down what investo...
January 24, 2022, 9:36 am
Tesla has the ability to follow amazon's path, says canaccord genuity analyst
Gordon Johnson, founder and CEO of GLJ Research, and Jed Dorsheimer, analyst at Canaccord Genuity, join CNBC's 'Squawk Box' to break down what investo...
January 24, 2022, 9:36 am
Uipath: at the forefront of robotic process automation
Uipath is at the forefront of the RPA industry fueled by multiple tailwinds with a large addressable ma...
January 24, 2022, 9:30 am
Uipath: at the forefront of robotic process automation
Uipath is at the forefront of the RPA industry fueled by multiple tailwinds with a large addressable ma...
January 24, 2022, 9:30 am
Uipath: at the forefront of robotic process automation
Uipath is at the forefront of the RPA industry fueled by multiple tailwinds with a large addressable ma...
January 24, 2022, 9:30 am
Ionis' eplontersen receives fda orphan drug status for misfolded protein disorder
The FDA has granted orphan drug designation to Ionis Pharmaceuticals Inc's (NASDAQ: IONS) eplontersen, an investigational antisense medicine for t...
January 24, 2022, 9:25 am
Ionis' eplontersen receives fda orphan drug status for misfolded protein disorder
The FDA has granted orphan drug designation to Ionis Pharmaceuticals Inc's (NASDAQ: IONS) eplontersen, an investigational antisense medicine for t...
January 24, 2022, 9:25 am
Ionis' eplontersen receives fda orphan drug status for misfolded protein disorder
The FDA has granted orphan drug designation to Ionis Pharmaceuticals Inc's (NASDAQ: IONS) eplontersen, an investigational antisense medicine for t...
January 24, 2022, 9:25 am
Lantern pharma's lp-184 receives rare pediatric, orphan drug tags for rare form of cancer
The FDA has granted Rare Pediatric Disease and Orphan Drug Designations to Lantern Pharma Inc's (NASDAQ: LTRN) LP-184 for Atypical Teratoid Rhabdo...
January 24, 2022, 7:34 am
Lantern pharma's lp-184 receives rare pediatric, orphan drug tags for rare form of cancer
The FDA has granted Rare Pediatric Disease and Orphan Drug Designations to Lantern Pharma Inc's (NASDAQ: LTRN) LP-184 for Atypical Teratoid Rhabdo...
January 24, 2022, 7:34 am
Lantern pharma's lp-184 receives rare pediatric, orphan drug tags for rare form of cancer
The FDA has granted Rare Pediatric Disease and Orphan Drug Designations to Lantern Pharma Inc's (NASDAQ: LTRN) LP-184 for Atypical Teratoid Rhabdo...
January 24, 2022, 7:34 am
Pfizer, opko shares fall after fda declines to approve somatrogon
Pfizer said it is evaluating the FDA's comments and will work with the agency "to determine an appropriate pat...
January 24, 2022, 7:27 am
Pfizer, opko shares fall after fda declines to approve somatrogon
Pfizer said it is evaluating the FDA's comments and will work with the agency "to determine an appropriate pat...
January 24, 2022, 7:27 am
Pfizer, opko shares fall after fda declines to approve somatrogon
Pfizer said it is evaluating the FDA's comments and will work with the agency "to determine an appropriate pat...
January 24, 2022, 7:27 am